2ouz
Crystal Structure of Estrogen Receptor alpha-lasofoxifene complex
|
OverviewOverview
Lasofoxifene is a new and potent selective estrogen receptor modulator, (SERM). The structural basis of its interaction with the estrogen receptor, has been investigated by crystallographic analysis of its complex with the, ligand-binding domain of estrogen receptor alpha at a resolution of 2.0 A., As with other SERMs, lasofoxifene diverts the receptor from its, agonist-bound conformation by displacing the C-terminal AF-2 helix into, the site at which the LXXLL motif of coactivator proteins would otherwise, be able to bind. Lasofoxifene achieves this effect by occupying the space, normally filled by residue Leu 540, as well as by modulating the, conformation of residues of helix 11 (His 524, Leu 525). A well-defined, salt bridge between lasofoxifene and Asp 351 suggests that charge, neutralization in this region of the receptor may explain the some of the, antiestrogenic effects of lasofoxifene. The results suggest general, features of ERalpha/SERM recognition, and add a new dimension to efforts, to rationalize differences between the biological activity profiles, exhibited by these important pharmacological agents.
DiseaseDisease
Known diseases associated with this structure: Atherosclerosis, susceptibility to OMIM:[133430], Breast cancer OMIM:[133430], Estrogen resistance OMIM:[133430], HDL response to hormone replacement, augmented OMIM:[133430], Migraine, susceptibility to OMIM:[133430], Myocardial infarction, susceptibility to OMIM:[133430]
About this StructureAbout this Structure
2OUZ is a Single protein structure of sequence from Homo sapiens with C3D as ligand. Full crystallographic information is available from OCA.
ReferenceReference
The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene., Vajdos FF, Hoth LR, Geoghegan KF, Simons SP, LeMotte PK, Danley DE, Ammirati MJ, Pandit J, Protein Sci. 2007 May;16(5):897-905. PMID:17456742
Page seeded by OCA on Mon Nov 12 23:16:43 2007